Bridgepoint Group Ltd / htl Biotechnology SAS / Montagu Private Equity SAS
Financial Advisor to Bridgepoint in divesting a majority in HTL Biotech, a pharmaceutical-grade Hyaluronic Acid (Hyaluronan) and other Glycosaminoglycans (GAGs) and other functional Biopolymers such as PDRN or Polynucleotides (PN) to Montagu.
Financial Advisor to Bridgepoint in the context of the divestiture of a majority stake in HTL Biotech to Montagu for EUR 1.2bn, preparation of Due Diligence Supporting Materials, Comprehensive analysis of all JV Partnerships, Licensing and Co-development Agreements, realization of a case-study evidencing the long-term sustainable win-win partnerships put in place by the Management of HTL Biotech as key value drivers for the future Acquirer. We evaluated as well the individual NPV of each collaboration partnership and an analysis on the pipeline of upcoming partnerships and realization of a fairness opinion analysis.